Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1380-1386

  Sprong, Tom ^a   Mollnes, Tom Eirik ^b,c   Neeleman, Chris ^a   Swinkels, Dorine ^a   Netea, Mihai G ^a   Van Der Meer, Jos W M ^a   Van Deuren, Marcel ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B BINDING PROTEIN; COMPLEMENT COMPONENT C4B; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EXON; FEMALE; GENE MUTATION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MENINGOCOCCEMIA; POINT MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ANIMALS; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; HUMANS; INFANT; MALE; MANNOSE-BINDING LECTIN; MENINGOCOCCAL INFECTIONS; SHOCK, SEPTIC;

EID: 72849142469     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606054     Document Type: Article

References (41)

1. Van Deuren M, Brandtzaeg P, Van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13:144-166 (Pubitemid 30039347)
2. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine Baltimore 1984; 63:243-273 (Pubitemid 14020907)
3. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-395 (Pubitemid 21920404)
4. Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160:58-65. (Pubitemid 19162994)
5. Hazelzet JA, de Groot R, van Mierlo G, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66:5350-5356
6. Jack DL, Dodds AW, Anwar N, et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998; 160:1346-1353 (Pubitemid 28093434)
7. Estabrook MM, Jack DL, Klien NJ, Jarvis GA. Mannose-binding lectin (MBL) binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis but not to lipooligosaccharide (LOS). J Immunol 2004; 172:3784-3792
8. Sprong T, Brandtzaeg P, Fung M, et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003; 102: 3702-3710 (Pubitemid 37409391) (Pubitemid 37409391)
9. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996; 17:532-540
10. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353:1049-1053 (Pubitemid 29149913) (Pubitemid 29149913)
11. Verdu P, Barreiro LB, Patin E, et al. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet 2006; 15:2650-2658 (Pubitemid 44288693) (Pubitemid 44288693)
12. Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004; 199:1295-1299 (Pubitemid 38685721) (Pubitemid 38685721)
13. Sprong T, Deuren MV. Mannose-binding lectin: ancient molecule, interesting future. Clin Infect Dis 2008; 47:517-518
14. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4: 133-142
15. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
16. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416-2421 (Pubitemid 39648222) (Pubitemid 39648222)
17. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
18. van Brakel MJ, van Vught AJ, Gemke RJ. Pediatric risk of mortality (PRISM) score in meningococcal disease. Eur J Pediatr 2000; 159:232-236
19. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 1979; 9: 186-188 (Pubitemid 9123780)
20. Fure H, Nielsen EW, Hack CE, Mollnes TE. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand J Immunol 1997; 46:553-557 (Pubitemid 28035415)
21. Wolbink GJ, Bollen J, Baars JW, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163:67-76. (Pubitemid 23213031)
22. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100:1869-1877 (Pubitemid 34925168)
23. Garred P, Mollnes TE, Lea T. Quantification in enzyme linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27:329-335 (Pubitemid 18076757)
24. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22:197-202. (Pubitemid 15016794) (Pubitemid 15016794)
25. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10:133-139
26. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155:3013-3020
27. Roelofs R, Sprong T, de Kok J, Swinkels D. PCR-restriction fragment length polymorphism method to detect the X/Y polymorphism in the promoter site of the mannose-binding lectin gene. Clin Chem 2003; 49:1557-1558 (Pubitemid 37011757) (Pubitemid 37011757)
28. Van Deuren M, Neeleman C, van t Hek LGFM, van der Meer JWM. A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Med 1998; 24: 157-161
29. Brandtzaeg P, Høgåsen K, Kierulf P, Mollnes TE. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 1996; 173:647-655 (Pubitemid 26064066)
30. Dumestre-Perard C, Doerr E, Colomb MG, Loos M. Involvement of complement pathways in patients with bacterial septicemia. Mol Immunol 2007; 44:1631-1638 (Pubitemid 44792746)
31. Bilgin YM, Brand A, Berger SP, Daha MR, Roos A. Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions. Transfusion 2008; 48:601-608
32. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 2004; 138:439-446 (Pubitemid 39573623) (Pubitemid 39573623)
33. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002; 1572:401-413
34. Biesma DH, Hannema AJ, van Velzen-Blad H, et al. A family with complement factor D deficiency. J Clin Invest 2001; 108:233-240
35. Sprong T, Roos D, Weemaes C, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006; 107:4865-4870 (Pubitemid 43882639) (Pubitemid 43882639)
36. Laudes IJ, Chu JC, Sikranth S, et al. Anti-C5a ameliorates coagulation/ fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160:1867-1875 (Pubitemid 34525666)
37. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77:394-398 (Pubitemid 27084936)
38. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28:184-192
39. Ota H, Fox-Talbot K, Hu W, et al. Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation 2005; 79:276-281 (Pubitemid 40299532) (Pubitemid 40299532)
40. Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006; 43:107-121
41. Bohle D, Stagl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med 2003; 31:S97-S104. (Pubitemid 36143483)